09 June 2026
EMA/MB/87650/2026
Management Board

DRAFT Agenda for the 132nd meeting of the Management Board

Held on 10 June 2026, Room 1C (15:30 – 18:30)
Held on 11 June 2025, Room 1C (09:00 – 16:00)

Chairperson: Rui Santos Ivo

Item	Title	**MB action**
1.	Draft agenda	For adoption, EMA/MB/87650/2026*
2.	Declarations of competing interests related to the agenda	Oral report
3.	Minutes from the 131ST meeting, held on 12 March 2026 adopted by written procedure	For information, EMA/MB/57340/2026*
A	**Points for automatic adoption/endorsement**	
A.1	Inflationary adjustment for rates payable to EDQM for sampling and testing activities in 2027	For information & endorsement, EMA/MB/46621/2026
A.2	MB Decision on implementing provisions on reimbursements of expenses for missions to the UK	For information, EMA/MB/71363/2026, EC-Ares(2026)2485874; For adoption, EMA/MB/71642/2026*
A.3	Revision to Single Programming Document	For information, EMA/MB/122306/2026 For adoption, EMA/MB/122309/2026*
A.4	Revision of the CAT Rules of Procedure	For information, EMA/MB/77410/2026; For adoption, EMA/68867/2026 (EMEA/45110/2007 Rev. 6)*
B	**Points for discussion**	
B.1	Highlights of the Executive Director	Oral report
B.2	Report from the European Commission	Oral report

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Item	Title	MB action
B.3	Preparation for implementation of the new EU pharmaceutical legislation (NPL): a) Legislative update (EC) b) Update from the NPL Oversight Group c) Implementation Roadmap	Oral report
B.4	a) Assessment of the Executive Director's Annual Activity Report (AAR) 2025 b) Annual accounts 2025 and launch of written procedure	For information, EMA/MB/120285/2026, EMA/95458/2026 For adoption, EMA/MB/107691/2026* For information, EMA/MB/112418 /2026
B.5	Annual report of 2025 on Key Performance Indicators (KPIs) for pre-authorisation, inspection, and scientific advice procedures for medicinal products for human and veterinary use	For information, EMA/MB/90942/2026; For endorsement, EMA/32231/2026;
B.6	Update on 'One substance - One assessment' (OSOA) framework (EC DG ENV and DG SANTE)	Oral report
B.7	Update on Audit topics a) Update on MB Audits and Risks Group (MBARG) b) 2025 activity report of the Agency's Internal Audit Capability c) 2026 half-year report of the Agency's Internal Audit Capability	Oral report For information, EMA/MB/91989/2026; For adoption, EMA/91988/2026; For information, EMA/MB/91989/2026
B.8	Clinical trials in the EU: • Policy and legislative update (EC) • Update on CTIS roadmap and budget • Update on other CT initiatives	Oral report; For information, EMA/MB/122260/2026, EMA/122221/2026
B.9	Network Portfolio Report: • Status update • Report Q1-2026	Oral report; For information, EMA/MB/127917/2026, EMA/115010/2026
B.10	Status update on African Medicines Agency (AMA)	Oral report
B.11	Update from Network Data Steering Group (NDSG)	Oral report
B.12	Fee Regulation working arrangements rev. 3	For information, EMA/MB/110072/2026; For adoption, EMA/183645/2024 Rev. 3*
C	**Points for information only****	
C.1	Outcome of written procedures finalised during the period from 5 March 2026 to 3 June 2026	For information, EMA/MB/68666/2026*

Item	Title	MB action
C.2	Summary report of implementation of assigned revenue June 2026	For information, EMA/MB/66679/2026
C.3	Summary of transfers of appropriations in budget 2026	For information, EMA/MB/122820/2026
C.4	Extension of mandate for Quality Working Party (QWP) and Biologics Working Party (BWP) members	For information, EMA/MB/103245/2026

* Documents marked with a star * are intended for publication on the external website.
** Documents in *Additional documents for information* section are not intended for discussion unless specifically requested.